Please Scroll Down to See Forums Below
Nolvadex forever?
- Thread starter big_boy_1
- Start date
It causes impotence and low libido according to the info sheet on it. Maybe thats a benefit if you are single, dunno.
http://www.rxlist.com/cgi/generic/tamox_ad.htm
"NOLVADEX is well tolerated in males with breast cancer. Reports from the literature and case reports suggest that the safety profile of NOLVADEX in males is similar to that seen in women. Loss of libido and impotence have resulted in discontinuation of tamoxifen therapy in male patients. Also, in oligospermic males treated with tamoxifen, LH, FSH, testosterone and estrogen levels were elevated. No significant clinical changes were reported."
http://www.rxlist.com/cgi/generic/tamox_ad.htm
"NOLVADEX is well tolerated in males with breast cancer. Reports from the literature and case reports suggest that the safety profile of NOLVADEX in males is similar to that seen in women. Loss of libido and impotence have resulted in discontinuation of tamoxifen therapy in male patients. Also, in oligospermic males treated with tamoxifen, LH, FSH, testosterone and estrogen levels were elevated. No significant clinical changes were reported."
Cauliflower Ear
New member
fuck that...i am not down with libido issues...although i have never had any
macrophage69alpha
New member
nolvadex is also hard on the liver, perhaps more so than 17aa steroids. It can cause DNA damage to the liver, non-alcoholic steatohepatitis, and liver cancer.
automaticj5
New member
Where did u find it at??
macrophage69alpha
New member
clomid does not have the negative impact on the liver that tamoxifen does.
letro may adversely affect lipid profile, but should not be considered hepatoxic.
AIFM should have little or no impact on the liver, it places about as much strain as injectables- which is pretty much none. It should actually slightly help to maintain HDL
letro may adversely affect lipid profile, but should not be considered hepatoxic.
AIFM should have little or no impact on the liver, it places about as much strain as injectables- which is pretty much none. It should actually slightly help to maintain HDL
macrophage69alpha
New member
1: AJR Am J Roentgenol. 2003 Jan;180(1):129-34. Related Articles, Links
Effects of tamoxifen on hepatic fat content and the development of hepatic steatosis in patients with breast cancer: high frequency of involvement and rapid reversal after completion of tamoxifen therapy.
Nishino M, Hayakawa K, Nakamura Y, Morimoto T, Mukaihara S.
Department of Radiology, Kyoto City Hospital, 1-2 Higashi-takada-cho, Mibu, Nakagyo-ku, Kyoto 604-8845, Japan.
OBJECTIVE: A study was conducted on hepatic fat content to investigate the frequency and clinical course of hepatic steatosis induced by tamoxifen. MATERIALS AND METHODS: Sixty-seven patients with breast cancer treated with adjuvant tamoxifen were included. The patients underwent postoperative annual abdominal CT, both with and without contrast enhancement, for 5 years. We retrospectively reviewed unenhanced CT images and obtained hepatic and splenic CT attenuation values to calculate the liver-spleen ratio. Hepatic steatosis was defined as a liver-spleen ratio of less than 0:9, and its degree was classified as mild (liver-spleen ratio, 0:5-0:9), moderate (0-0:5), or severe (<0). The pattern of steatosis was classified as generalized, lobar, segmental, or focal. RESULTS: In the study population, hepatic CT values decreased during therapy (p < 0.0001, t test) and increased after therapy (p < 0.0001, paired t test). Twenty-nine patients (43.2%) developed hepatic steatosis within the first 2 years; its degree was mild in 16, moderate in nine, and severe in four. Seventeen patients showed a generalized pattern of steatosis, and the other 12 showed a lobar pattern. Twenty-three of these patients showed an increase in the liver-spleen ratio after therapy to within the normal range, with a mean recovery time of 1.2 years after therapy ended. None progressed to steatohepatitis or cirrhosis. CONCLUSION: Tamoxifen had a statistically significant influence on hepatic fat content and was associated with frequent development of hepatic steatosis. Radiologists should be aware of this phenomenon and the possible occurrence of hepatic dysfunction and should differentiate steatosis from metastasis in postoperative patients with breast cancer.
Gastroenterol Hepatol. 2002 Apr;25(4):247-50. Related Articles, Links
[Toxic hepatitis associated with tamoxifen use. A case report and literature review]
[Article in Spanish]
Lasso De La Vega MC, Zapater P, Such J, Sola-Vera J, Paya A, Horga JF, Perez-Mateo M.
Unidad de Farmacologia Clinica, Hospital General Universitario de Alicante, Spain. [email protected]
Tamoxifen is an antiestrogenic drug that acts by binding to the estrogen receptor. The drug is used as a co-adjuvant treatment in advanced breast cancer expressing the oestrogen-receptor protein. Clinical trials of tamoxifen have shown its efficacy in reducing mortality and recurrence rates over a five-year treatment. Cases of tamoxifen-associated hepatotoxicity have been described, including cholestasis with or without cytolysis and steatohepatitis. We report the case of a female patient who developed hepatic alterations while undergoing continuous tamoxifen treatment. We also present an overview of similar cases published to date and comment on the advisability of continuing or suppressing this treatment in patients with hepatotoxicity or after a five-year treatment period.
J Hepatol. 1995 Jul;23(1):95-7. Related Articles, Links
Tamoxifen-associated steatohepatitis--report of three cases.
Pinto HC, Baptista A, Camilo ME, de Costa EB, Valente A, de Moura MC.
Department of Medicine, University Hospital Santa Maria, Lisbon, Portugal.
The authors describe three cases of tamoxifen-associated steatohepatitis, which resulted from a daily dosage of 20 mg used as the adjuvant treatment of breast carcinoma. Liver tests became normal after discontinuation of tamoxifen.
Of course these women were not also using anabolic steroids....
Effects of tamoxifen on hepatic fat content and the development of hepatic steatosis in patients with breast cancer: high frequency of involvement and rapid reversal after completion of tamoxifen therapy.
Nishino M, Hayakawa K, Nakamura Y, Morimoto T, Mukaihara S.
Department of Radiology, Kyoto City Hospital, 1-2 Higashi-takada-cho, Mibu, Nakagyo-ku, Kyoto 604-8845, Japan.
OBJECTIVE: A study was conducted on hepatic fat content to investigate the frequency and clinical course of hepatic steatosis induced by tamoxifen. MATERIALS AND METHODS: Sixty-seven patients with breast cancer treated with adjuvant tamoxifen were included. The patients underwent postoperative annual abdominal CT, both with and without contrast enhancement, for 5 years. We retrospectively reviewed unenhanced CT images and obtained hepatic and splenic CT attenuation values to calculate the liver-spleen ratio. Hepatic steatosis was defined as a liver-spleen ratio of less than 0:9, and its degree was classified as mild (liver-spleen ratio, 0:5-0:9), moderate (0-0:5), or severe (<0). The pattern of steatosis was classified as generalized, lobar, segmental, or focal. RESULTS: In the study population, hepatic CT values decreased during therapy (p < 0.0001, t test) and increased after therapy (p < 0.0001, paired t test). Twenty-nine patients (43.2%) developed hepatic steatosis within the first 2 years; its degree was mild in 16, moderate in nine, and severe in four. Seventeen patients showed a generalized pattern of steatosis, and the other 12 showed a lobar pattern. Twenty-three of these patients showed an increase in the liver-spleen ratio after therapy to within the normal range, with a mean recovery time of 1.2 years after therapy ended. None progressed to steatohepatitis or cirrhosis. CONCLUSION: Tamoxifen had a statistically significant influence on hepatic fat content and was associated with frequent development of hepatic steatosis. Radiologists should be aware of this phenomenon and the possible occurrence of hepatic dysfunction and should differentiate steatosis from metastasis in postoperative patients with breast cancer.
Gastroenterol Hepatol. 2002 Apr;25(4):247-50. Related Articles, Links
[Toxic hepatitis associated with tamoxifen use. A case report and literature review]
[Article in Spanish]
Lasso De La Vega MC, Zapater P, Such J, Sola-Vera J, Paya A, Horga JF, Perez-Mateo M.
Unidad de Farmacologia Clinica, Hospital General Universitario de Alicante, Spain. [email protected]
Tamoxifen is an antiestrogenic drug that acts by binding to the estrogen receptor. The drug is used as a co-adjuvant treatment in advanced breast cancer expressing the oestrogen-receptor protein. Clinical trials of tamoxifen have shown its efficacy in reducing mortality and recurrence rates over a five-year treatment. Cases of tamoxifen-associated hepatotoxicity have been described, including cholestasis with or without cytolysis and steatohepatitis. We report the case of a female patient who developed hepatic alterations while undergoing continuous tamoxifen treatment. We also present an overview of similar cases published to date and comment on the advisability of continuing or suppressing this treatment in patients with hepatotoxicity or after a five-year treatment period.
J Hepatol. 1995 Jul;23(1):95-7. Related Articles, Links
Tamoxifen-associated steatohepatitis--report of three cases.
Pinto HC, Baptista A, Camilo ME, de Costa EB, Valente A, de Moura MC.
Department of Medicine, University Hospital Santa Maria, Lisbon, Portugal.
The authors describe three cases of tamoxifen-associated steatohepatitis, which resulted from a daily dosage of 20 mg used as the adjuvant treatment of breast carcinoma. Liver tests became normal after discontinuation of tamoxifen.
Of course these women were not also using anabolic steroids....
macrophage69alpha
New member
Med Oncol. 2002;19(2):121-3. Related Articles, Links
Tamoxifen-related porphyria cutanea tarda.
Agarwal R, Peters TJ, Coombes RC, Vigushin DM.
Section of Medicine, Institute of Cancer Research, Sutton, Surrey, United Kingdom. [email protected]
We report a case of porphyria cutanea tarda (PCT) in a patient with breast cancer following adjuvant tamoxifen. Cessation of tamoxifen resulted in a prompt decline in urinary porphyrins suggestive of a causative role. Tamoxifen is known to be hepatotoxic; however, its association with PCT is unclear. In this report, we discuss the porphyrinogenicity of tamoxifen and potential mechanisms.
Tamoxifen-related porphyria cutanea tarda.
Agarwal R, Peters TJ, Coombes RC, Vigushin DM.
Section of Medicine, Institute of Cancer Research, Sutton, Surrey, United Kingdom. [email protected]
We report a case of porphyria cutanea tarda (PCT) in a patient with breast cancer following adjuvant tamoxifen. Cessation of tamoxifen resulted in a prompt decline in urinary porphyrins suggestive of a causative role. Tamoxifen is known to be hepatotoxic; however, its association with PCT is unclear. In this report, we discuss the porphyrinogenicity of tamoxifen and potential mechanisms.
macrophage69alpha
New member
just go on pubmed- and search
tamoxifen genotoxic
tamoxifen hepatotoxic
tamoxifen libido
nolva is not all puppy dog tails and fairy wishes..
tamoxifen genotoxic
tamoxifen hepatotoxic
tamoxifen libido
nolva is not all puppy dog tails and fairy wishes..
G
gettinripped
Guest
hey macro,
do you take nolvadex?? is it safe if used in small amount, say for pct for no more than 4-6 weeks at doses no more than 40mg ed?? do you recommend using aifm in place of nolva as well. if so, that shit is the wonder spray. glad i have 2 bottles.
do you take nolvadex?? is it safe if used in small amount, say for pct for no more than 4-6 weeks at doses no more than 40mg ed?? do you recommend using aifm in place of nolva as well. if so, that shit is the wonder spray. glad i have 2 bottles.
macrophage69alpha
New member
gettinripped said:
no
its probably fine, but the liver and other issues are just things to consider in your decision making. Also keeping in mind that progestins and nolva DO NOT MIX.
yes. While AIFM can be used alone for PCT, generally reccomend low dose HCG as well. If you want to use a SERM, clomid. Now some people do respond better to nolva or find clomid unpalatable. So nolva can be used, but most people use to much and fail to account for its REDICULOUSLY long half life.
G
gettinripped
Guest
can you fill me in on a progestin?? what is it?? so pct, aifm and hcg only?? this is you preferred method and you recover well every time??
Similar threads
